Article

Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients

2022-04-18

Abstract excerpt

<h4>Importance</h4> In patients with hematologic malignancies, the immunogenicity of the standard 2-dose mRNA-1273 coronavirus disease 19 (COVID-19) vaccination schedule is often insufficient due to underlying disease and current or recent therapy. <h4>Objective</h4> To determine whether a 3 rd mRNA-1273 vaccination raises antibody concentrations in immunocompromised hematology patients to levels obtained in healt...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6a63c7e5-9c4a-557a-90a4-857085fe2c37
DOI: 10.1101/2022.04.08.22273602

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patientsDOI 10.1101/2022.04.08.22273602Read

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals.Semantic proximity Read

Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic MalignanciesSemantic proximity Read

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialSemantic proximity Read

Longitudinal Vaccine-Induced Humoral Immune Response in Cancer PatientsSemantic proximity Read

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisSemantic proximity Read

A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 dosesSemantic proximity Read

The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBDSemantic proximity Read

Immunogenicity and Omicron Neutralization Following a Third COVID-19 Vaccination in Solid Cancer Patients Previously Primed with Two Doses of Chadox1 Vaccine: A Prospective Cohort StudySemantic proximity Read

COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic reviewSemantic proximity Read

Class switching toward IgG4 six months after primary mRNA-based COVID-19 vaccination in kidney patientsSemantic proximity Read

Profiling antibody epitopes induced by mRNA-1273 vaccination and boostersSemantic proximity Read

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boostersSemantic proximity Read